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CObjective: To estimate quality-adjusted life-year weights for patients
with diabetic retinopathy by using various methods and to investigate
the empirical validity of the different measures. Methods: The study
population comprised 152 patients with diabetes in Östergötland
County, Sweden. Participants were interviewed by telephone by using
the time trade-off (TTO) method and a visual analogue scale (EQ-VAS)
(direct valuations) as well as the EuroQol five-dimensional question-
naire (EQ-5D) and the health utilities index mark 3 (HUI-3) (indirect
valuations). The quality-adjusted life-year weights were adjusted for
potential confounders by using analysis of covariance. The empirical
validity of the measures was examined by testing their ability to detect
hypothetical differences between severity levels of diabetic retinopa-
thy and by investigating the correlation between the measures and the
25-item National Eye Institute Visual Function Questionnaire (NEI
VFQ-25). Results: All measures detected significant differences in scoresetween patient groups classified according to visual impairment in the O
l adv
ical c
hare
echn
al So
oi:10.1016/j.jval.2011.11.031etter eye (analysis of covariance, P  0.05), but only HUI-3 and EQ-VAS
etected significant differences between patient groups classified accord-
ng to visual impairment or pathological progression in the worse eye.
UI-3 recorded a difference of 0.43 in values between normal vision and
lindness in the better eye, which was more than twice the differences
aptured by the other measures (0.15–0.20). In addition, HUI-3 showed
he highest correlation with NEI VFQ-25 (r  0.54; P  0.001).
onclusions: In cost-utility analyses, the choice of quality-adjusted
ife-year measure may affect whether an intervention is considered
ost-effective. Furthermore, if decisions are to be based on values from
he general public, HUI-3 can be recommended for cost-utility analyses
f interventions directed at diabetic retinopathy.
eywords: diabetes mellitus, diabetic retinopathy, EQ-5D, health utility
ndex mark 3, NEI-VFQ-25, QALY, time trade-off, TTO, VAS.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In cost-effectiveness analyses used to inform decision makers
about the cost-effectiveness of alternative interventions, quality-
adjusted life-years (QALYs) have been recommended as the main
effect outcome measure [1,2]. By combining the effect on survival
and health-related quality of life (HRQOL) into one measure and
enabling comparisons across different disease areas, QALYs have
become a common measure of health outcome and treatment ef-
fect. To calculate QALYs, the time in a specific health state is mul-
tiplied by a score representing the value of that specific health
state (death is represented by 0 and full health by 1).
The value of health states can be estimated by using various
measures. These measures include direct valuation methods such
as standard gamble (SG) [3], time trade-off (TTO) [4], and the visual
analogue scale (VAS) [5] as well as indirect questionnaire-based
measures such as the health utilities index mark 3 (HUI-3) [6], the
EuroQol five-dimensional questionnaire (EQ-5D) [7], the 15-D mea-
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Rosenqvist has lectured and worked as a consultant at pharmaceut
AstraZeneca, and Bristol-Myers Squibb. None of the authors has s
* Address correspondence to: Emelie Heintz, Center for Medical T
inköping University, SE 581 83 Linköping, Sweden.
E-mail: emelie.heintz@liu.se.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.sure [8], and the six-dimensional health state short form (SF-6D,
derived from short form 36 health survey) [9]. There are various
methodological differences between these measures. For exam-
ple, when used on patient populations, the values estimated with
the direct and indirect measures represent different respondent
perspectives. The direct methods are used to capture values that
patients assign to their own health state, whereas the indirect
measures use published tariffs to assign values of the general pub-
lic to patients’ descriptions of their health. In addition, the indirect
measures differ in what dimensions their questionnaires include,
how many response levels each question has, and the direct val-
uation method used to create the tariff. Concerning the direct
methods, the most important difference is that the values of the
TTO and SG methods are elicited by asking respondents to choose
between different scenarios, while the VAS is based on a rating
exercise. However, there are also methodological differences be-
tween TTO and SG.
Despite the dissimilarities between the measures, in practice
they are often used interchangeably. For instance, in Sweden
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476 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 7 5 – 4 8 4pharmacoeconomic guidelines state that patient values elicited by
using direct choice-based methods are preferred [10]; however, in
the absence of these, decision makers accept valuations from the
general public and from any of the above-mentioned direct or in-
direct methods. If the measures give different results, the choice of
measure could, when measuring the effectiveness of an interven-
tion, play an important role, which could potentially have an im-
pact on whether an intervention is considered cost-effective. Var-
ious studies have suggested that the measures do give different
results (e.g., [11–15]). Though, because the performance of the
measures may depend on the characteristics of the health state
being valued, there is a need to investigate how these measures
behave in specific disease areas.
In the previous literature concerning QALY weights for the di-
abetic eye complication diabetic retinopathy (DR), patient valua-
tions with TTO have been the most commonly used method [16].
ost of these studies, however, used vision-specific questions in
hich patients were asked to trade life years for full vision rather
han full health. This vision-specific version operates on another
cale and has previously been argued to overestimate the decre-
ents in HRQOL related to visual impairment compared with con-
entional methods [17,18]. Relatively few studies have used indi-
ect measures to estimate QALY weights for DR [16]. Thus, to be
ble to populate decision models in line with guidelines in differ-
nt countries, there is still a need for QALY weights for DR based
n patient as well as general public values. These weights should
e classified according to the pathological progression of DR, be-
ause this is the dominating primary end point in clinical studies
19–21]. Few studies have compared the performance of measures
mong patients with DR, and results have varied [22,23]. The aim
f the current article, therefore, was to elicit QALY weights for DR
nd to investigate the empirical validity of QALY measures in pa-
ients with different severity levels of DR.
Methods
Study population
The study population consisted of 152 patients with diabetes
(types 1 and 2) living in the county of Östergötland, Sweden. In this
county, all patients with diabetes are included in a screening pro-
gram for DR. The study included patients attending these screen-
ing examinations at the eye clinic of Linköping University Hospital
in 2008 to 2009. Because patients with the most severe vision loss
are normally excluded from the screening program, we recruited
these patients through two low vision rehabilitation centers in
Östergötland. To be eligible for inclusion in the study, participants
had to have had diabetes for at least 1 year and be at least 18 years
old. After giving informed consent, including access to their med-
ical records, patients with cataract, glaucoma, or other eye disease
compromising visual acuity (VA) were excluded from the study.
Other exclusions were those with dietary treatment only, patients
with Alzheimer’s disease, dementia, or difficulty understanding
instructions because of very old age, patients with severe concom-
itant disease that could affect the quality of life (as judged by the
physician who included patients in the study), and patients who
did not have a sufficient level of understanding Swedish to com-
plete the interview. In the inclusion process, we strived for an
equal distribution of types 1 and 2 diabetes. The study was ap-
proved by the Regional Ethical Review Board of the county of
Östergötland in Linköping (DNR: M115-08).
Patient classification
Patients were, based on the worse eye, recruited to one of five
severity groups representing the following health states: no DR
(Early Treatment Diabetic Retinopathy Study level 10), background aretinopathy (BR; levels 20–53), proliferative diabetic retinopathy
(PDR; level 60 or treated earlier with panretinal photocoagula-
tion), diabetic macular edema (DME; defined in accordance with
Early Treatment Diabetic Retinopathy Study guidelines for clini-
cally significant macular edema or treated earlier for clinically sig-
nificant macular edema), and legal blindness (Snellen VA 20/200
n the better eye). These health states have previously been used in
ecision models [24–27]. Legal blindness represented the end
oint of the disease. A sample size calculation (  5% and 1 –  
80%) via the F distribution was performed on the basis of previ-
ously published data on mean values (no DR 0.94, BR 0.87, PDR 0.83,
legal blindness 0.81) and standard deviation (SD) (0.14) [28]. The
calculation gave a sample size of at least 25 participants in each
severity level. Grading of the patients into the severity levels was
performed by an ophthalmologist on the basis of photographs
taken during the screening appointment. Dilated pupil, red-free
fundus photography (Topcon Retina Camera T3C 50 IX, Topcon
Corporation, Tokyo, Japan) was performed in both eyes in the fol-
lowing fields: optic nerve, central fundus, and temporal, superial,
and inferior retina. If both PDR and DME were present in the same
eye, the patient was classified as having DME, because this was
assumed to affect patients’ VA more than PDR. Besides the classi-
fication based on pathological progression of the disease, patients
were also divided into four groups on the basis of their Snellen VA
in the better eye (using International Classification of Diseases, Ninth
Revision, Clinical Modification/World Health Organization criteria):
normal vision (defined as VA 20/10–20/25), mild visual impairment
(VA 20/32–20/63), moderate visual impairment (VA 20/80–20/160),
and severe visual impairment (VA  20/200). The VA was checked
during the screening appointment. In line with standard proce-
dure, a trained ophthalmic nurse started each screening visit by
assessing best-corrected VA starting with the right eye, followed
by the left eye, using a 5-m Snellen chart.
Data collection
Included patients were contacted and interviewed over the tele-
phone. Each interview lasted approximately 45 minutes and in-
cluded two direct valuation methods, TTO and EQ-VAS, and two
indirect generic multiattribute instruments, HUI-3 and EQ-5D. In
addition, the 25-item National Eye Institute Visual Function Ques-
tionnaire (NEI-VFQ-25) was used to collect vision-specific informa-
tion. The instruments were administered in the same order for all
patients. The order was the following: HUI-3, TTO, EQ-5D, EQ-VAS,
and NEI-VFQ-25. All interviews were performed by the same
trained researcher (E.H.). Background information and data on the
duration of diabetes, type of diabetes, and other diabetes compli-
cations were collected from patient records. In the few cases
where information was not available in the patient records (hemo-
globin A1c value for one patient and diabetes duration for another),
ata were complemented by asking the patients.
Direct valuation
In the TTO method [4], the preferences of each respondent for a
specific health state are elicited by asking the respondent to
choose between two different health states, each assigned a spe-
cific number of years followed by death. In the present study, re-
spondents were asked to choose between living in their current
health state for their remaining life expectancy (t), followed by
death, and a state of full health for a shorter period (x), also fol-
lowed by death. The time x was varied until the number of years
was found for which the respondent was indifferent between the
two alternatives. The TTO value was calculated by dividing x by
he time of the first alternative t. The remaining life expectancy
sed in the questions was based on the Swedish population’s av-
rage remaining survival (rounded to the nearest decade) for the
ge and sex group of the respondent [29]. For the EQ-VAS rating
477V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 7 5 – 4 8 4scale [7], which is a separate part of the EQ-5D, respondents are
asked to estimate their own health on a scale from 0 to 100, with 0
representing the worst imaginable health state and 100 the best.
Multiattribute instruments
With both HUI-3 [6] and EQ-5D [7], information on the respon-
dent’s health status is collected by asking the respondent to com-
plete a specific health questionnaire or by conducting an interview
following a detailed interview manual. The responses in the ques-
tionnaires can then be scored by using published tariffs that have
been derived by using one of the direct valuation methods. In this
study, we have for both these instruments used specific versions
that have been developed for telephone interviews [30,31]. The
HUI-3 interview manual consists of 41 questions, and the included
questions concern how respondents perceive their own HRQOL in
the dimensions of vision, hearing, speech, ambulation, dexterity,
emotion, cognition, and pain (Table 1). The health description re-
sulting from the questionnaire was scored by using a multiattrib-
ute scoring function with values elicited from a random sample of
the Canadian general population (n  504) by using VAS in com-
bination with the SG method. The EQ-5D interview manual con-
sists of five questions, each representing one HRQOL dimension:
mobility, self-care, usual activities, pain/discomfort, and anxiety/
depression. In each dimension, respondents can classify them-
selves into one of three levels of severity: no problems, some prob-
lems, and extreme problems. The scoring function used in the
present study was derived from a random sample of the general
population in the United Kingdom (n 3395) [32] by using the TTO
method.
NEI-VFQ-25
NEI-VFQ-25 [33] assesses how eye disease affects a patient’s
ability to live without pain, to work productively, and to interact
with family and friends. The results can be presented as an
overall score or as a health profile using 12 dimensions (Table 1).
The NEI-VFQ-25 composite score is presented as an index be-
tween 0 and 100, with 0 representing the worse possible score
and 100 the best. It assumes equal intervals between the re-
sponse choices within each dimension, and the composite score
of the measure is an unweighted average of all attributes except
Table 1 – Comparison of the measures.
Measure Possible
range
Dimensions
HUI-3 0.36 to 1.00 Vision, hearing, speech,
ambulation, dexterity,
emotion, cognition, pain
EQ-5D 0.59 to 1.00 Mobility, self-care, usual
activities, pain/discomfort,
anxiety/depression
EQ-VAS 0–100 N/A
TTO 0–1.00 N/A
NEI-VFQ-25 0–100 General health, general vision,
ocular pain, near activities,
distance activities, social
functioning, mental health,
role difficulties, dependency,
driving, color vision and
peripheral vision
EQ-5D, EuroQol five-dimensional questionnaire; EQ-VAS, EuroQol Vis
ble; NEI-VFQ-25, 25-item National Eye Institute Visual Functioning
analogue scale.for general health.Statistical analysis
All patients who answered all questions in the four generic mea-
sures were included in the analysis. The bakground characteris-
tics are presented as proportions of patients or mean values with
SD. For each generic measure, adjusted mean scores (QALY
weights) and 95% confidence intervals were calculated for the se-
verity levels by using analysis of covariance models. The models’ F
statistics were used to obtain a measure of the methods’ ability to
detect differences between the severity levels. The variables in-
cluded in the adjustment were age, sex, diabetes duration, hemo-
globin A1c level (Mono S), cardiovascular disease (known periph-
eral vascular disease, transient ischemic attack/stroke, angina
pectoris/myocardial infarction, or previous vascular intervention),
neuropathy (clinical signs of any form of neuropathy mentioned in
the patient’s clinical record), and nephropathy (proteinuria and/or
an increase in serum creatinine level). The adjusted scores were
calculated on the basis of the distribution of these variables in the
no-DR group. Sex and age were included in the model because
these variables previously have been seen to have an effect on
HRQOL [34]. In addition, all variables presented in Table 2 except
for visual impairment and the NEI VFQ-25 scores were considered
for inclusion in the model because they a priori were believed to
affect the HRQOL of the patients. However, they were included in
the model only if they differed between the severity levels of DR.
The residuals were tested for non-normality and heteroscedastic-
ity by plotting the residuals toward the fitted values and using the
Breusch-Pagan test. Because the residuals were found to be het-
eroscedastic, this was corrected for by using White’s robust stan-
dard errors [35]. This approach has been recommended when the
purpose is to inform economic evaluations [36]. The model was
also tested for multicolinearity, but none of the variables had a
variance inflation factor (VIF) of more than 2. When relevant, pair-
wise comparisons were made via analysis of variance corrected
with the Tukey-Kramer procedure [37]. The statistical software
used for the basic analyses was STATA/IC 10.1 (Stata Corp LP,
Texas, USA). The adjustment with analysis of covariance was per-
formed in SAS 9.1.3 (SAS Institute Inc, North Carolina, USA).
Comparison of valuation methods
In evaluating the performance of QALY measures, comparisons
can be made in terms of practicality, reliability, and validity [38].
ponse
vels
Valuation technique Valuation sample
5–6 SG and VAS 504 representatives of the
general population in
Canada
3 TTO 3 395 representatives from
the general population
in UK
N/A VAS Study participants
N/A TTO Study participants
6 Average of the scores
in the dimensions
N/A
nalogue Scale; HUI-3, health utilities index mark 3; N/A, not applica-
stionnaire; SG, standard gamble; TTO, time trade-off; VAS, visualRes
le
ual A
QueThe last of these, validity, concerns to what extent the measures
sing F
478 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 7 5 – 4 8 4measure what they are intended to do. Ideally, this would be
tested by comparing the results of the measure to a gold standard.
However, because no such gold standard exists for QALY weights,
other more indirect methods have been recommended. Empirical
validity measures to what degree the measure is able to identify or
measure what it is supposed to in practice. One way of doing this
is to study whether the measure generates QALY weights that are
in line with expected differences between groups of patients, so-
called hypothetical preferences. This method has previously been
used to investigate the validity of QALY measures in various dis-
ease areas [15,39–43].
The empirical validity of the measures in this study was exam-
ined by testing a hypothetical preference rule that the scores
should differ significantly between groups with different severity
levels of DR and that the scores should decrease with disease se-
verity. The ability of the measures to detect differences in HRQOL
between patient groups was compared by using relative efficiency
statistics [44]. The relative efficiency of the measures was calcu-
lated by taking the square of the F statistic of the comparator
measure divided by the square of the F statistic of the reference
measure (the measure with the lowest F statistic). The adjusted
scores from the generic measures were also tested toward the
Table 2 – Clinical and sociodemographic characteristics by
No
retinopathy
(n  35)
BR (n 
Mean SD Mean
Age (y) 51.06 17.31 57.62
Hb A1c (Mono S) 6.48 1.05 7.08
Diabetes duration 11.03 8.08 21.54
NEI-VFQ-25 score 96.37 4.94 95.29
n % n
Sex (women) 12 34.3 14
Type 1 diabetes 17 48.6 18
Neuropathy 0 0.0 5
Nephropathy 0 0.0 5
Cardiovascular disease 4 11.4 7
Visual impairment (best eye)
Normal vision 34 97.1 36
Mild visual impairment 1 2.9 1
Moderate visual impairment 0 0.0 0
Severe visual impairment 0 0.0 0
Visual impairment (worse eye)
Normal vision 34 97.1 35
Mild visual impairment 1 2.9 2
Moderate visual impairment 0 0.0 0
Severe visual impairment 0 0.0 0
Smoker 4 11.4 4
Former smoker (of nonsmokers) 15 48.4 18
Education*
Nine-year compulsory school and/
or upper secondary school
21 60.0 25
Vocational training or university 14 40.0 12
Civil status
Married or cohabiting 25 71.4 31
Single, divorced, or widower 10 28.6 6
BR, background retinopathy; DME, diabetic macular edema; DR, diabe
Institute Visual Functioning Questionnaire; PDR, proliferative diabeti
* Data missing on one patient. Normal vision was defined as VA 2
impairment as VA 20/80-20/160, and severe visual impairment as
variance using the F test, and the proportions were compared by upatients’ VA and their results from the NEI-VFQ-25 by calculatingthe Spearman’s rank correlation coefficient. Our assumption was
that health states with higher VA or a higher score on the NEI-
VFQ-25 scale would be preferable to health states with lower
scores. Spearman’s rank correlation coefficient was chosen as the
main measure of correlation, because we were primarily inter-
ested in the correlation between the measures’ ranking of individ-
uals and not the correlation between the absolute values. A corre-
lation was considered moderate if it exceeded 0.30 and strong if it
exceeded 0.5 [45]. To investigate whether any of the measures had
a higher correlation with any of the external indicators (NEI-
VFQ-25 and VA) than did the other measures, the correlations
were tested against each other by using Wolfe’s test for comparing
dependent correlation coefficients [46].
Results
Of the 251 patients who were asked to participate, 152 were in-
cluded in the analysis (their clinical and sociodemographic char-
acteristics are described in Table 2). Of those who were excluded,
24 chose not to participate and 61 were excluded either on exclu-
sion criteria (after assessment of full patient records) or because
rity level of DR in the worse eye.
PDR (n  26) DME (n  31) Legal
blindness
(n  23)
P
Mean SD Mean SD Mean SD
0 51.69 13.05 58.19 12.09 67.00 11.07 0.001
7 7.60 1.53 7.35 1.26 6.95 1.08 0.004
2 27.50 11.29 19.58 9.55 33.00 19.92 0.001
8 88.68 13.22 90.86 10.67 49.63 21.68 0.001
n % n % n % P
12 46.2 7 22.6 7 30.4 0.432
17 65.4 15 48.4 12 52.2 0.670
6 23.1 4 12.9 12 52.2 0.001
7 26.9 4 12.9 11 47.8 0.001
3 11.5 5 16.1 11 47.8 0.015
21 80.8 21 67.7 2 8.7
0.001
5 19.2 9 29.0 1 4.4
0 0.0 1 3.2 5 21.7
0 0.0 0 0.0 15 65.2
13 50.0 17 54.8 0 0.0
0.001
10 38.5 9 29.0 0 0.0
3 11.5 5 16.1 0 0.0
0 0.0 0 0.0 23 100.0
1 3.9 3 9.7 2 8.7 0.903
11 44.0 14 50.0 13 61.9 0.791
18 69.2 23 76.7 17 73.9
0.680
8 30.8 7 23.3 6 26.1
19 73.1 22 71.0 18 78.3
0.680
7 26.9 9 29.0 5 21.7
tinopathy; Hb A1c, hemoglobin A1c; NEI-VFQ-25, 25-item National Eye
nopathy; VA, visual acuity.
20/25, mild visual impairment as VA 20/32-20/63, moderate visual
f 20/200 or less. The means were compared by one-way analysis of
isher’s exact test.seve
37)
SD
13.4
0.9
13.1
7.1
%
37.8
48.7
13.5
13.5
18.9
97.3
2.7
0.0
0.0
94.6
5.4
0.0
0.0
10.8
54.6
67.6
32.4
83.8
16.2
tic re
c reti
0/10-
VA othey were not reachable at the time of the telephone interview. In
479V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 7 5 – 4 8 4Table 3 – QALY weights (95% CI) for different severity levels of DR and the relative efficiency (RE) of the measures in
detecting differences in HRQoL between the severity levels.
Valuation
method
Classification n Measure outcome F P RE
Severity level in the worse eye Unadjusted mean value (95% CI)
HUI-3 No DR 35 0.88 (0.83–0.93)
20.71 0.001 8.59
BR 37 0.78 (0.69–0.86)
PDR 26 0.81 (0.74–0.88)
DME 31 0.79 (0.73–0.86)
Blindness 23 0.39 (0.26–0.51)
EQ-5D No DR 35 0.81 (0.75–0.86)
3.26 0.01 1.35
BR 37 0.72 (0.61–0.83)
PDR 26 0.77 (0.68–0.87)
DME 31 0.81 (0.74–0.88)
Blindness 23 0.59 (0.45–0.74)
TTO No DR 35 0.85 (0.79–0.92)
2.41 0.05 1.00
BR 37 0.78 (0.71–0.86)
PDR 26 0.78 (0.70–0.86)
DME 31 0.82 (0.74–0.89)
Blindness 23 0.68 (0.54–0.81)
EQ-VAS No DR 35 80.51 (77.33–83.70)
5.74 0.001 2.38
BR 37 72.16 (66.14–78.18)
PDR 26 75.46 (68.59–82.33)
DME 31 74.48 (68.25–80.72)
Blindness 23 59.96 (51.55–68.36)
Severity level in the worse eye Adjusted mean*value (95% CI)
HUI-3 No DR 35 0.88 (0.81–0.95)
9.22 0.001 98.29
BR 37 0.85 (0.77–0.93)
PDR 26 0.89 (0.79–0.99)
DME 31 0.86 (0.78–0.95)
Blindness 23 0.53 (0.41–0.66)
EQ-5D No DR 35 0.81 (0.73–0.89)
1.87 0.12 4.04
BR 37 0.77 (0.68–0.86)
PDR 26 0.83 (0.71–0.94)
DME 31 0.86 (0.76–0.96)
Blindness 23 0.67 (0.52–0.81)
TTO No DR 35 0.85 (0.78–0.93)
0.93 0.45 1.00
BR 37 0.81 (0.73–0.89)
PDR 26 0.83 (0.73–0.94)
DME 31 0.83 (0.74–0.92)
Blindness 23 0.72 (0.59–0.85)
EQ-VAS No DR 35 80.51 (75.36–85.67)
3.12 0.02 11.25
BR 37 73.84 (68.04–79.63)
PDR 26 77.74 (70.36–85.12)
DME 31 77.03 (70.71–83.36)
Blindness 23 63.26 (53.93–72.59)
Severity level in the better eye Adjusted mean*value (95% CI)
HUI-3 No DR 39 0.88 (0.82–0.95)
9.81 0.001 75.37
BR 48 0.86 (0.79–0.93)
PDR 32 0.87 (0.78–0.97)
DME 18 0.83 (0.72–0.93)
Blindness 15 0.48 (0.34–0.61)
EQ-5D No DR 39 0.82 (0.74–0.89)
1.13 0.34 1.00
BR 48 0.78 (0.69–0.86)
PDR 32 0.84 (0.73–0.95)
DME 18 0.86 (0.73–1.00)
Blindness 15 0.69 (0.52–0.85)
TTO No DR 39 0.87 (0.80–0.93)
3.51 0.01 9.65
BR 48 0.78 (0.71–0.86)
PDR 32 0.81 (0.72–0.91)
DME 18 0.89 (0.78–1.00)
Blindness 15 0.62 (0.48–0.77)(continued on next page)
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480 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 7 5 – 4 8 4addition, 14 individuals were excluded from analysis because of
missing data.
The percentages of patients reporting a score equivalent to
full health, that is, a score of 1.0, was 8%, 24%, 26%, and 0% for
HUI-3, TTO, EQ-5D, and EQ-VAS, respectively. HUI-3 resulted in
scores below zero for two patients (1%); for EQ-5D, the corre-
sponding number was six patients (4%). As expected, the mean
NEI-VFQ-25 composite scores decreased with progression of the
disease (Table 2). All the measures were able to identify signif-
cant differences between the different groups of visual impair-
ent in the better eye (Table 4), but neither TTO nor EQ-5D
dentified any significant differences between the severity lev-
ls classified according to the pathological progression or visual
mpairment in the worse eye (Tables 3 and 4). In addition, EQ-5D
id not identify significant differences between the severity lev-
ls classified according to the better eye. For all measures, the
ignificant differences were mainly due to blindness (pair-wise
omparisons corrected with Tukey-Kramer) and for the less se-
ere states the scores did not always follow the hypothesized
rdering (Tables 3 and 4). DME and PDR had in some cases
igher scores than BR and in a few cases even higher than no
R. This was particularly evident in the results from EQ-5D and
TO, independent of classification according to the better eye or
he worse eye. Even when patients were classified according to
isual impairment in the better eye, TTO and EQ-5D resulted in
score ordering that contradicted our hypothesized expecta-
ions.
When the patients were classified according to the worse
ye, HUI-3 resulted in scores higher than those from other mea-
ures for all severity levels except blindness, for which HUI-3 in
ontrast recorded the lowest score. Of the four measures, EQ-
AS gave the lowest score for the levels before blindness (the
ess severe health states) and TTO had the highest score for
lindness (the most severe health state). Figure 1 and Table 3
how that the difference in HRQOL between PDR or less severe
R and blindness is larger if measured with HUI-3 (a difference
f approximately 0.36) than with any of the other measures. The
ifference is smallest with the EQ-5D score (approximately
.16). Compared with the other measures, HUI-3 had the highest
elative efficiency (i.e., was the most efficient), independent of
hether the patients were classified on the basis of pathological
rogression of DR or their visual impairment (Tables 3 and 4).
UI-3 also had a significantly higher correlation with VA (in the
etter and worse eye) and with NEI-VFQ-25 (Table 5) than did
he other measures. The Spearman’s rank correlation between
UI-3 and NEI-VFQ-25 was 0.54 (P  0.001), meaning that the
anking of the patients according to HUI-3 correlated strongly
ith the ranking according to vision-specific measures. The
ther measures’ ranking showed only low to moderate correla-
Table 3 (continued)
Valuation
method
Classification n
EQVAS No DR 39
BR 48
PDR 32
DME 18
Blindness 15
* Adjusted for age, sex, diabetes duration, HbA1c (Mono S), cardiovas
BR, background retinopathy; CI, confidence interval; DME, diabetic m
questionnaire; EQ-VAS, EuroQol Visual Analogue Scale; HUI-3, healt
efficiency; TTO, time trade-off.ion with the ranking according to VA and NEI-VFQ-25.Discussion
Main findings
In this study, we estimated QALY weights for DR with four HRQOL
measures and investigated their performance in patients with DR
by examining whether they can identify hypothesized differences
between severity levels and how well their results correlate with
external indicators of the severity of DR. The results showed that
all four measures identified significant differences between the
groups of visual impairment in the better eye but only HUI-3 and
EQ-VAS detected significant differences between the patient
groups classified according to the visual impairment or patholog-
ical progression in the worse eye. Contrary to our expectations, the
scores did not always follow the progression of the disease. Of the
four measures, HUI-3 was the most sensitive at detecting differ-
ences between severity levels, with an HRQOL decrement for
blindness that was at least two times greater than that of the other
measures. The HUI-3 ranking was also found to have a stronger
correlation with the ranking according to visual function. This
large difference between HUI-3 and the other measures implies
that their estimates could, if used in cost-effectiveness analyses,
lead to different conclusions concerning the cost-effectiveness of
an intervention.
Our results correspond well with those of Espallargues et al. [14],
ho showed that HUI-3 is more sensitive than EQ-5D, TTO, and VAS
n detecting differences in HRQOL due to macular degeneration
which is a condition with a effect similar to that of DR on VA). Fur-
hermore, in a comparison of EQ-5D, SF-6D, and the 15-D measure,
ontodimopoulos et al. [23] showed that the 15-D measure, which,
like HUI-3, has a specific dimension for vision, is more sensitive to DR
than are the other measures. In contrast, Lloyd et al. [22] found that
HUI-3 and EQ-5D yield similar decrements in HRQOL as DR pro-
gresses. It is however unclear whether the values presented in the
latter were adjusted for comorbidities. Regarding the results from our
TTO question, the decrement from normal vision to blindness was
smaller than in previous TTO studies [16]. However, the vision-spe-
cific TTO versions that have been used in most previous studies have
been argued to overestimate the effects of visual impairment [17,18].
Inconsistent ordering of the scores has previously been ob-
served by Lloyd et al. [22], who suggested that this finding may
be related to the loss of independence in the early stages of
visual impairment. In our study, however, the inconsistency
was mostly related to relatively low scores for patients with BR,
which is an asymptomatic stage of the disease and is not ex-
pected to be associated with loss of independence (when the
patients were classified according to VA, this was reflected in
relatively low scores in the group with normal vision). Patients
with BR had a higher proportion of cardiovascular disease, but
this was adjusted for in the analysis of covariance. It is possible,
Measure outcome F P RE
80.59 (75.74–85.44)
3.66 0.01 10.49
74.67 (69.40–79.94)
76.70 (69.54–83.86)
76.94 (68.75–85.13)
60.08 (49.79–70.37)
disease, neuropathy and nephropathy.
ar edema; DR, diabetic retinopathy; EQ-5D, EuroQol five-dimensional
ities index mark 3; PDR, proliferative diabetic retinopathy; RE, relativecular
acul
h utilhowever, that we failed to adjust for some other important di-
disea
; HUI-
481V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 7 5 – 4 8 4abetes-related variable. In a more detailed analysis of the di-
mensions included in HUI-3 and EQ-5D, the group of patients
with BR was found to have a higher proportion of problems with
Table 4 – QALY weights (95% CI) for different levels of visio
in detecting differences in HRQoL between impairment lev
Valuation
method
Classification n
Visual impairment in the worse eye
HUI-3 Normal vision 99
Mild visual impairment 22
Moderate visual impairment 8
Severe visual impairment 23
EQ-5D Normal vision 99
Mild visual impairment 22
Moderate visual impairment 8
Severe visual impairment 23
TTO Normal vision 99
Mild visual impairment 22
Moderate visual impairment 8
Severe visual impairment 23
EQ-VAS Normal vision 99
Mild visual impairment 22
Moderate visual impairment 8
Severe visual impairment 23
Visual impairment in the worse eye
HUI-3 Normal vision 99
Mild visual impairment 22
Moderate visual impairment 8
Severe visual impairment 23
EQ-5D Normal vision 99
Mild visual impairment 22
Moderate visual impairment 8
Severe visual impairment 23
TTO Normal vision 99
Mild visual impairment 22
Moderate visual impairment 8
Severe visual impairment 23
EQ-VAS Normal vision 99
Mild visual impairment 22
Moderate visual impairment 8
Severe visual impairment 23
Visual impairment in the better eye
HUI-3 Normal vision 114
Mild visual impairment 17
Moderate visual impairment 6
Severe visual impairment 15
EQ-5D Normal vision 114
Mild visual impairment 17
Moderate visual impairment 6
Severe visual impairment 15
TTO Normal vision 114
Mild visual impairment 17
Moderate visual impairment 6
Severe visual impairment 15
EQ-VAS Normal vision 114
Mild visual impairment 17
Moderate visual impairment 6
Severe visual impairment 15
* Adjusted for age, sex, diabetes duration, HbA1c (Mono S), cardiovascular
five-dimensional questionnaire; EQ-VAS, EuroQol Visual Analogue Scaledexterity. Given this unexpected finding and the fact that thedifferences in scores between the early stages are not signifi-
cant, we would advise users of our results to set the QALY
weight for BR at equal to no DR until we know more about the
pairment and the relative efficiency (RE) of the measures
Measure outcome F P RE
Unadjusted mean
value (95% CI)
0.82 (0.78–0.86)
25.94 0.001 9.98
0.81 (0.76–0.87)
0.77 (0.59–0.96)
0.39 (0.26–0.51)
0.77 (0.72–0.82)
3.92 0.01 1.51
0.83 (0.77–0.89)
0.77 (0.71–0.83)
0.59 (0.45–0.74)
0.82 (0.78–0.86)
2.60 0.05 1.00
0.78 (0.69–0.88)
0.79 (0.58–1.00)
0.68 (0.54–0.81)
75.95 (72.73–79.17)
6.79 0.001 2.61
77.82 (72.48–83.15)
67.50 (50.00–85.00)
59.96 (51.55–68.36)
Adjusted mean* value
(95% CI)
0.82 (0.78–0.86)
13.16 0.001 12.78
0.90 (0.81–1.00)
0.81 (0.66–0.95)
0.51 (0.40–0.62)
0.77 (0.72–0.82)
2.52 0.06 2.45
0.87 (0.76–0.98)
0.78 (0.61–0.96)
0.66 (0.53–0.79)
0.82 (0.78–0.86)
1.03 0.38 1.00
0.81 (0.71–0.91)
0.81 (0.65–0.96)
0.71 (0.59–0.83)
75.95 (72.90–79.00)
4.17 0.01 4.05
80.43 (73.26–87.59)
69.20 (58.14–80.25)
63.89 (55.66–72.13)
Adjusted mean* value
(95% CI)
0.83 (0.79–0.86)
17.49 0.001 5.59
0.81 (0.71–0.91)
0.53 (0.37–0.70)
0.40 (0.28–0.52)
0.78 (0.73–0.82)
3.28 0.03 1.05
0.84 (0.72–0.97)
0.54 (0.34–0.75)
0.63 (0.48–0.77)
0.82 (0.78–0.85)
3.13 0.03 1.00
0.79 (0.68–0.90)
0.85 (0.67–1.03)
0.62 (0.49–0.75)
76.18 (73.37–78.98)
5.62 0.001 1.80
75.59 (67.81–83.36)
61.70 (48.71–74.69)
58.10 (49.06–67.14)
se, neuropathy and nephropathy. CI, confidence interval; EQ-5D, EuroQol
3, health utilities index mark 3; RE, relative efficiency; TTO, time trade-off.n im
els.reason behind the decrement in this group.
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482 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 7 5 – 4 8 4Concerning the differences between the direct and indirect
measures, patients have previously been found to report higher
scores than the general public [47–49], especially for severe health
states. A possible reason is that patients adapt to their own health
state. This corresponds well with our results for HUI-3, where
HUI-3 gave lower scores for blindness than did the direct mea-
sures. Adaption could perhaps also explain why patients with
moderate visual impairment reported higher TTO scores than did
those with no or mild visual impairment. In addition, the ques-
tionnaires of the indirect methods, such as EQ-5D and HUI-3, limit
patients’ descriptions of their health states to specific dimensions.
It has been argued that potentially positive aspects that would be
captured with the direct methods might be missed by the indirect
estimations [50]. On the other hand, it could be argued that pa-
tients do not take their vision into account when responding to the
TTO questions. When patients had finished the TTO exercise,
however, they were asked whether they had considered full health
as also including full vision, and 60% stated that they had. Of those
who had not, 80% (vs. 73% among those who had done so) had
normal vision. Further research on this subject is required to learn
more about the role of vision in TTO exercises.
Of the indirect measures, HUI-3 has an advantage over EQ-5D
when used for patients with diseases leading to visual impair-
ment, because it includes a specific dimension for vision and fo-
cuses more on functional impairment. For example, while the di-
mensions Mobility in EQ-5D and Ambulation in HUI-3 may seem
very similar, the framing of the questions differ. In EQ-5D, the
respondents are asked about their ability to walk with or without
difficulties, but in HUI-3, the focus is on whether they can walk
around the neighborhood without help from anyone and/or with-
out walking equipment. Because a patient with visual impairment
may not have difficulties with moving in general but may need
some sort of guidance or support when walking from one place to
another, these questions may give completely different results.
Fig. 1 – Adjusted QALY weights for different severity levels
of DR based on the worse eye. The weights are adjusted for
age, sex, diabetes duration, hemoglobin A1c level,
ardiovascular disease, neuropathy, and nephropathy. The
ifferences are calculated by subtracting the score for
lindness from that of PDR. BR, background retinopathy;
ME, diabetic macular edema; DR, diabetic retinopathy;
Q-5D, EuroQol five-dimensional questionnaire; EQ-VAS,
uroQol Visual Analogue Scale; HUI-3, health utilities
ndex mark 3; PDR, proliferative diabetic retinopathy; TTO,
ime trade-off.Furthermore, the measures differ because their tariffs have beenelicited by using different valuation methods and modeling tech-
niques. While the tariff for EQ-5D is based on TTO values, the
HUI-3 tariff is derived from a combination of SG and VAS. TTO and
SG have previously been found to give different results [51].
When comparing the two direct methods, EQ-VAS gave lower
scores than did TTO, in line with previous literature [51]. A possible
explanation could be that no patient reported full health with EQ-
VAS but it could also be due to the different methodologies. Because
EQ-VAS is not a choice-based method, many do not consider it an
appropriate method for estimating QALY weights.
Limitations
This article has a number of limitations that need to be discussed.
First, the questionnaires were administered in the same order to
all patients. This could potentially have biased our comparison of
measures because of carryover effects or fatigue. Administration
order, however, has been found in various previous studies to
have no or only a marginal effect on HRQOL measurements [52–
54]. Furthermore, we believe that the administration of the study by
telephone required patients to answer actively, reducing the risk of
fatigue, and this was supported by the patients’ tone of voice. Never-
theless, caution is warranted when comparing the results of the
measures, especially because HUI-3, which was the first measure in
our interviews, was found to be the most sensitive.
Second, we did not use any visual support for the TTO and
EQ-VAS exercises. Because of the severe visual impairment of
some of the patients in the study, using any form of visual aid
could have resulted in a severe bias, because those patients would
not have been able to use any such aid. In addition, TTO and EQ-
VAS exercises administered by telephone have previously been
found to give similar results as do face-to-face interviews [55–57].
Our TTO question could also be considered to have an advantage
over those of other studies, because the years patients were will-
ing to trade were elicited by using “ping-pong” questions rather
than an open-ended question.
Third, our sample size was relatively small. This could explain
why there were no large differences between the stages prior to
Table 5 – Spearman’s rank correlation between NEI-
VFQ-25, Snellen visual acuity, and the generic HRQOL
measures.
r
HUI-3 EQ-5D
score
TTO EQ-VAS
NEI-VFQ-25 0.54 0.27 0.33 0.32
Visual acuity (worse eye) 0.59 0.31 0.35 0.34
Visual acuity (better eye) 0.50 0.24 0.28 0.27
HUI-3 0.70 0.58 0.73
EQ-5D score 0.52 0.97
TTO 0.46
All correlations were significantly higher than 0 (P  0.01). The cor-
relations between HUI-3 and the external indicators of severity of
DR (NEI-VFQ-25 and visual acuity) were significantly higher than
the correlations between the other measures and the external in-
dicators (tested with Wolfe’s test for comparing dependent corre-
lation coefficients). The scores from the generic measures were ad-
justed for age, sex, diabetes duration, Hb A1c level, cardiovascular
disease, neuropathy, and nephropathy.
EQ-5D, EuroQol five-dimensional questionnaire; EQ-VAS, EuroQol
Visual Analogue Scale; Hb A1c, hemoglobin A1c; HRQOL, health-re-
lated quality of life; HUI-3, health utilities index mark 3; NEI-VFQ-
25, 25-item National Eye Institute Visual Functioning Question-
naire; TTO, time trade-off.
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483V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 4 7 5 – 4 8 4blindness. However, because the more severe levels for some mea-
sures had even higher scores than did the less severe levels, it is
not likely that these would have been associated with significant
decrements, even if we have had a larger sample. In addition, the
lack of significant decrements could also be explained by the fact
that patients with more severe levels of DR had better vision than
expected.
Fourth, our classification of the patients into severity levels
according to the pathological progression of DR could be ques-
tioned. A combination of VA and contrast sensitivity has been
recommended for classifying patients into different severity levels
relevant for their HRQOL [58]. In this study, however, we were
ooking for QALY weights that could be used to populate decision
odels, and many of the models [24–27] that have been developed
in the DR field have been based on the pathological progression in
the worse eye. Even though HRQOL may mostly be affected by the
patients’ ability to see, worries about the disease may also affect
their HRQOL. In addition, treatment effect and costs are related to
the pathological state of the eye. However, because there were
such small differences in values between the stages prior to blind-
ness, we also decided to present values for different degrees of VA.
Implications
The fact that there are differences between the sensitivity of the
measures and that they give different decrements for blindness
may have important policy implications. In cost-utility analyses of
interventions directed at DR, the choice of measure could have a
significant impact on the incremental cost per QALY. Imagine that
a new treatment for DR, compared with the standard treatment,
prevents one additional patient from progressing from PDR to
blindness (on the worse eye) at the age of 60 years and that the
patient, independent of his or her eye condition, would live until
the age of 80 years. Using the estimates from HUI-3 (Fig. 1), this
would result in an incremental effect of 7.2 QALYs (0.36  20),
hile the estimates from EQ-5D would give an incremental effect
f 3.2 QALYs (0.16 20). If we also assumed that the new treatment
osts GBP 150,000 (1.601 GBP/USD July 7, 2011) more per case of
lindness prevented, this would result in a cost per QALY of ap-
roximately GBP 21,000 and GBP 47,000 for HUI-3 and EQ-5D, re-
pectively. As many decision-making bodies, such as the National
nstitute of Clinical Excellence in the United Kingdom, use a
hreshold of GBP 20,000 to 30,000 [59] to determine whether a treat-
ent is cost-effective, the choice of measure could have an impor-
ant influence on whether a treatment is implemented.
Where it is likely that the results of different measures diverge,
here are various aspects that should be considered when choos-
ng between measures. On a policy level, it should be determined
hether the decisions concerning the allocation of resources are
o be based on patient values or on values of the general public. In
ur study, the choice would be between direct patient valuation
ith TTO or EQ-VAS and indirect valuation based on public values
ith HUI-3 or EQ-5D. If the chosen policy is compromised because
f the lack of relevant measures, decision makers should be aware
hat this may give other results. On a more practical level, assum-
ng that the measures are practical and reliable, it is important to
onsider whether they are able to capture the effect of the specific
isease on HRQOL [39]. This can be achieved by studying the con-
truct of the measures in terms of face and content validity and by
nvestigating whether the instruments capture hypothesized dif-
erences (empirical validity). Our findings concerning the sensitiv-
ty of HUI-3 and its correlation with visual function suggest that
UI-3 captures DR-related differences in HRQOL that are not de-
ected by EQ-5D. This could be explained by differences in the
easures’ construct. Thus, if choosing between measures based
n public values, we would recommend HUI-3 for cost-effective-
ess calculations related to interventions directed at DR. Regard-ng the direct measures, none of the measures correlated stronglyith visual function but EQ-VAS showed values that were more in
ine with the hypothesized ordering than TTO. We would not rec-
mmend EQ-VAS, however, for use in cost-effectiveness analyses
ecause it is not a choice-based method. Other studies have solved
he insensitivity of TTO by using vision-specific TTO questions.
he use of these vision-specific questions in cost-utility analysis is
uestionable, however [17,18]. Therefore, future research is nec-
ssary on the role of vision in direct valuation exercises.
Conclusions
In conclusion, our study has shown that the choice of measure for
estimation of QALY weights for cost-utility analyses matters, be-
cause it may have an impact on whether an intervention is con-
sidered cost-effective. This is of interest not only to those conduct-
ing future cost-utility analyses of interventions directed at DR but
also to decision makers evaluating cost-effectiveness evidence for
interventions directed at patients with comprised vision. Further-
more, the study suggests that HUI-3 is the most sensitive measure
for detecting differences in HRQOL due to DR and that it can, if
decisions are to be made on the basis of values from the general
public, be recommended for use in cost-utility analyses of inter-
ventions directed at DR.
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